Inhibition of glycogen synthase kinase-3Β prevents NSAID-induced acute kidney injury

Kidney International

Volumn 81, Issue 7, 2012, Pages 662-673

  Bao, Hao ^a,b   Ge, Yan ^b   Zhuang, Shougang ^b   Dworkin, Lance D ^b   Liu, Zhihong ^a   Gong, Rujun ^b  

^a NANJING UNIVERSITY   (China)

^b BROWN UNIVERSITY   (United States)

Author keywords

acute kidney injury; cyclooxygenase 2; diclofenac; glycogen synthase kinase 3 ; mitochondrial permeability transition; nonsteroidal anti inflammatory drugs

Indexed keywords

4 BENZYL 2 METHYL 1,2,4 THIAZOLIDINE 3,5 DIONE; ADENOSINE TRIPHOSPHATE; CREATININE; CYCLOOXYGENASE 2; CYCLOPHILIN D; DICLOFENAC; GLYCOGEN SYNTHASE KINASE 3BETA;

ACUTE KIDNEY FAILURE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BODY WEIGHT; CELL VIABILITY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOSE RESPONSE; DOWN REGULATION; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; IN VITRO STUDY; IN VIVO STUDY; KIDNEY MASS; KIDNEY TUBULE FUNCTION; KIDNEY TUBULE NECROSIS; LOW DRUG DOSE; MOUSE; NEPHROTOXICITY; NONHUMAN; OXIDATION REDUCTION STATE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENAL PROTECTION;

EID: 84862820297     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2011.443     Document Type: Article

References (45)

1. Rubio GJA, Tellez MMJ. [Acute renal failure and nephrotic syndrome associated with treatment with diclofenac]. Rev Clin Esp 1992; 191: 289-290.
2. Cicuttini L, Colatutto A, Pellegrini MA et al. [Acute reversible renal insufficiency during treatment with diclofenac]. Clin Ter 1989; 128: 81-86.
3. Masubuchi Y, Nakayama S, Horie T. Role of mitochondrial permeability transition in diclofenac-induced hepatocyte injury in rats. Hepatology 2002; 35: 544-551.
4. Uyemura SA, Santos AC, Mingatto FE et al. Diclofenac sodium and mefenamic acid: Potent inducers of the membrane permeability transition in renal cortex mitochondria. Arch Biochem Biophys 1997; 342: 231-235.
5. Mingatto FE, Santos AC, Uyemura SA et al. In vitro interaction of nonsteroidal anti-inflammatory drugs on oxidative phosphorylation of rat kidney mitochondria: Respiration and ATP synthesis. Arch Biochem Biophys 1996; 334: 303-308.
6. Gomez-Lechon MJ, Ponsoda X, O'Connor E et al. Diclofenac induces apoptosis in hepatocytes. Toxicol In Vitro 2003; 17: 675-680.
7. Gomez-Lechon MJ, Ponsoda X, O'Connor E et al. Diclofenac induces apoptosis in hepatocytes by alteration of mitochondrial function and generation of ROS. Biochem Pharmacol 2003; 66: 2155-2167.
8. Hickey EJ, Raje RR, Reid VE et al. Diclofenac induced in vivo nephrotoxicity may involve oxidative stress-mediated massive genomic DNA fragmentation and apoptotic cell death. Free Radic Biol Med 2001; 31: 139-152.
9. Kotnik P, Nielsen J, Kwon TH et al. Altered expression of COX-1, COX-2, and mPGES in rats with nephrogenic and central diabetes insipidus. Am J Physiol Renal Physiol 2005; 288: F1053-F1068.
10. Kwon TH. Dysregulation of renal cyclooxygenase-2 in rats with lithiuminduced nephrogenic diabetes insipidus. Electrolyte Blood Press 2007; 5: 68-74.
11. Juhaszova M, Zorov DB, Kim SH et al. Glycogen synthase kinase-3beta mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. J Clin Invest 2004; 113: 1535-1549.
12. Xi J, Wang H, Mueller RA et al. Mechanism for resveratrol-induced cardioprotection against reperfusion injury involves glycogen synthase kinase 3beta and mitochondrial permeability transition pore. Eur J Pharmacol 2009; 604: 111-116.
13. Wang SH, Shih YL, Kuo TC et al. Cadmium toxicity toward autophagy through ROS-activated GSK-3beta in mesangial cells. Toxicol Sci 2009; 108: 124-131.
14. Murray MD, Brater DC. Renal toxicity of the nonsteroidal antiinflammatory drugs. Annu Rev Pharmacol Toxicol 1993; 33: 435-465.
15. Gong R, Rifai A, Ge Y et al. Hepatocyte growth factor suppresses proinflammatory NFkappaB activation through GSK3beta inactivation in renal tubular epithelial cells. J Biol Chem 2008; 283: 7401-7410.
16. Gong R, Rifai A, Dworkin LD. Activation of PI3K-Akt-GSK3beta pathway mediates hepatocyte growth factor inhibition of RANTES expression in renal tubular epithelial cells. Biochem Biophys Res Commun 2005; 330: 27-33.
17. Nelson PJ, Cantley L. GSK3beta plays dirty in acute kidney injury. J Am Soc Nephrol 2010; 21: 199-200.
18. Ge Y, Si J, Tian L et al. Conditional ablation of glycogen synthase kinase 3beta in postnatal mouse kidney. Lab Invest 2011; 91: 85-96.
19. Wang Z, Havasi A, Gall J et al. GSK3beta promotes apoptosis after renal ischemic injury. J Am Soc Nephrol 2010; 21: 284-294.
20. Wang Q, Zhou Y, Wang X et al. Glycogen synthase kinase-3 is a negative regulator of extracellular signal-regulated kinase. Oncogene 2006; 25: 43-50.
21. Ng LE, Halliwell B, Wong KP. Nephrotoxic cell death by diclofenac and meloxicam. Biochem Biophys Res Commun 2008; 369: 873-877.
22. Stierlin H, Faigle JW. Biotransformation of diclofenac sodium (Voltaren) in animals and in man. II. Quantitative determination of the unchanged drug and principal phenolic metabolites, in urine and bile. Xenobiotica 1979; 9: 611-621.
23. Zhai P, Sadoshima J. Overcoming an energy crisis?: An adaptive role of glycogen synthase kinase-3 inhibition in ischemia/reperfusion. Circ Res 2008; 103: 910-913.
24. Yao LL, Huang XW, Wang YG et al. Hydrogen sulfide protects cardiomyocytes from hypoxia/reoxygenation-induced apoptosis by preventing GSK-3beta-dependent opening of mPTP. Am J Physiol Heart Circ Physiol 2010; 298: H1310-H1319.
25. Zorov DB, Juhaszova M, Yaniv Y et al. Regulation and pharmacology of the mitochondrial permeability transition pore. Cardiovasc Res 2009; 83: 213-225.
26. Plotnikov EY, Kazachenko AV, Vyssokikh MY et al. The role of mitochondria in oxidative and nitrosative stress during ischemia/ reperfusion in the rat kidney. Kidney Int 2007; 72: 1493-1502.
27. Sileikyte J, Petronilli V, Zulian A et al. Regulation of the inner membrane mitochondrial permeability transition by the outer membrane translocator protein (peripheral benzodiazepine receptor). J Biol Chem 2011; 286: 1046-1053.
28. Baines CP, Kaiser RA, Purcell NH et al. Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death. Nature 2005; 434: 658-662.
29. Green DR, Reed JC. Mitochondria and apoptosis. Science 1998; 281: 1309-1312.
30. Bereiter-Hahn J, Jendrach M. Mitochondrial dynamics. Int Rev Cell Mol Biol 2010; 284: 1-65.
31. Pessayre D, Mansouri A, Berson A et al. Mitochondrial involvement in drug-induced liver injury. Handb Exp Pharmacol 2010; 196: 311-365.
32. Ng LE, Vincent AS, Halliwell B et al. Action of diclofenac on kidney mitochondria and cells. Biochem Biophys Res Commun 2006; 348: 494-500.
33. Lemasters JJ, Qian T, Bradham CA et al. Mitochondrial dysfunction in the pathogenesis of necrotic and apoptotic cell death. J Bioenerg Biomembr 1999; 31: 305-319.
34. Varela AT, Simoes AM, Teodoro JS et al. Indirubin-30-oxime prevents hepatic I/R damage by inhibiting GSK-3beta and mitochondrial permeability transition. Mitochondrion 2010; 10: 456-463.
35. Dugo L, Abdelrahman M, Murch O et al. Glycogen synthase kinase-3beta inhibitors protect against the organ injury and dysfunction caused by hemorrhage and resuscitation. Shock 2006; 25: 485-491.
36. Alam I, Warden SJ, Robling AG et al. Mechanotransduction in bone does not require a functional cyclooxygenase-2 (COX-2) gene. J Bone Miner Res 2005; 20: 438-446.
37. Gong R, Rifai A, Tolbert EM et al. Hepatocyte growth factor ameliorates renal interstitial inflammation in rat remnant kidney by modulating tubular expression of macrophage chemoattractant protein-1 and RANTES. J Am Soc Nephrol 2004; 15: 2868-2881.
38. Ma X, Yang Q, Wilson KT et al. Promoter methylation regulates cyclooxygenase expression in breast cancer. Breast Cancer Res 2004; 6: R316-R321.
39. Cho JH, Johnson GV. Primed phosphorylation of tau at Thr231 by glycogen synthase kinase 3beta (GSK3beta) plays a critical role in regulating tau's ability to bind and stabilize microtubules. J Neurochem 2004; 88: 349-358.
40. Gong R, Rifai A, Dworkin LD. Anti-inflammatory effect of hepatocyte growth factor in chronic kidney disease: Targeting the inflamed vascular endothelium. J Am Soc Nephrol 2006; 17: 2464-2473.
41. Zhuang S, Kinsey GR, Yan Y et al. Extracellular signal-regulated kinase activation mediates mitochondrial dysfunction and necrosis induced by hydrogen peroxide in renal proximal tubular cells. J Pharmacol Exp Ther 2008; 325: 732-740.
42. Stoyanovsky DA, Vlasova II, Belikova NA et al. Activation of NO donors in mitochondria: Peroxidase metabolism of (2-hydroxyamino-vinyl)-triphenyl- phosphonium by cytochrome c releases NO and protects cells against apoptosis. FEBS Lett 2008; 582: 725-728.
43. Nieminen AL, Saylor AK, Tesfai SA et al. Contribution of the mitochondrial permeability transition to lethal injury after exposure of hepatocytes to t-butylhydroperoxide. Biochem J 1995; 307(Pt 1): 99-106.
44. Chen S, Ge Y, Si J et al. Candesartan suppresses chronic renal inflammation by a novel antioxidant action independent of AT1R blockade. Kidney Int 2008; 74: 1128-1138.
45. Ohori K, Miura T, Tanno M et al. Ser9 phosphorylation of mitochondrial GSK-3beta is a primary mechanism of cardiomyocyte protection by erythropoietin against oxidant-induced apoptosis. Am J Physiol Heart Circ Physiol 2008; 295: H2079-H2086.